serw-MX  [xml]  
 


    
 DeCS Categories

D02 Organic Chemicals .
D02.033 Alcohols .
D02.033.100 Amino Alcohols .
D02.033.100.624 Propanolamines .
D02.033.100.624.698 Phenoxypropanolamines .
D02.033.100.624.698.708 Prenalterol .
D02.033.755 Propanols .
D02.033.755.624 Propanolamines .
D02.033.755.624.698 Phenoxypropanolamines .
D02.033.755.624.698.708 Prenalterol .
D02.065 Amides .
D02.065.884 Sulfonamides .
D02.065.884.725 Sulfanilamides .
D02.065.884.725.867 Sulfamethoxazole .
D02.065.884.725.867.500 Trimethoprim, Sulfamethoxazole Drug Combination .
D02.092 Amines .
D02.092.063 Amino Alcohols .
D02.092.063.624 Propanolamines .
D02.092.063.624.698 Phenoxypropanolamines .
D02.092.063.624.698.708 Prenalterol .
D02.092.146 Aniline Compounds .
D02.092.146.807 Sulfanilamides .
D02.092.146.807.867 Sulfamethoxazole .
D02.092.146.807.867.500 Trimethoprim, Sulfamethoxazole Drug Combination .
D02.705 Organophosphorus Compounds .
D02.705.400 Organophosphates .
D02.705.400.625 Organothiophosphates .
D02.705.400.625.800 Temefos .
D02.705.539 Organothiophosphorus Compounds .
D02.705.539.345 Organothiophosphates .
D02.705.539.345.800 Temefos .
D02.886 Sulfur Compounds .
D02.886.300 Organothiophosphorus Compounds .
D02.886.300.692 Organothiophosphates .
D02.886.300.692.800 Temefos .
D02.886.590 Sulfones .
D02.886.590.700 Sulfonamides .
D02.886.590.700.725 Sulfanilamides .
D02.886.590.700.725.867 Sulfamethoxazole .
D02.886.590.700.725.867.500 Trimethoprim, Sulfamethoxazole Drug Combination .
D03 Heterocyclic Compounds .
D03.383 Heterocyclic Compounds, 1-Ring .
D03.383.742 Pyrimidines .
D03.383.742.906 Trimethoprim .
D03.383.742.906.500 Trimethoprim, Sulfamethoxazole Drug Combination .
D03.633 Heterocyclic Compounds, Fused-Ring .
D03.633.100 Heterocyclic Compounds, 2-Ring .
D03.633.100.810 Quinolines .
D03.633.100.810.835 Quinolones .
D03.633.100.810.835.322 Fluoroquinolones .
D03.633.100.810.835.322.750 Pefloxacin .
D12 Amino Acids, Peptides, and Proteins .
D12.776 Proteins .
D12.776.124 Blood Proteins .
D12.776.124.790 Serum Globulins .
D12.776.124.790.651 Immunoglobulins .
D12.776.124.790.651.114 Antibodies .
D12.776.124.790.651.114.580 Immunoconjugates .
D12.776.124.790.651.114.580.225 Abatacept .
D12.776.377 Globulins .
D12.776.377.715 Serum Globulins .
D12.776.377.715.548 Immunoglobulins .
D12.776.377.715.548.114 Antibodies .
D12.776.377.715.548.114.580 Immunoconjugates .
D12.776.377.715.548.114.580.225 Abatacept .
D26 Pharmaceutical Preparations .
D26.310 Drug Combinations .
D26.310.875 Trimethoprim, Sulfamethoxazole Drug Combination .
F03 Mental Disorders .
F03.875 Somatoform Disorders .
F03.875.300 Conversion Disorder .
J01 Technology, Industry, and Agriculture .
J01.576 Industry .
J01.576.423 Food Industry .
J01.576.423.200 Food Handling .
J01.576.423.200.700 Meat-Packing Industry .
J01.576.423.200.700.100 Abattoirs .
J03 Non-Medical Public and Private Facilities .
J03.540 Manufacturing and Industrial Facilities .
J03.540.020 Abattoirs .
 
 Terms
 Synonyms & Historicals
Documents
LILACS e MDL
 
Trimethoprim, Sulfamethoxazole Drug Combination .
Abactrim .
Bactifor .
Bactrim .
Biseptol .
Biseptol-480 .
Centran .
Centrin .
Co-Trimoxazole .
Cotrimoxazole .
Drylin .
Eslectin .
Eusaprim .
Insozalin .
Kepinol .
Kepinol Forte .
Lescot .
Metomide .
Oriprim .
Septra .
Septrin .
Sulfamethoxazole-Trimethoprim Combination .
Sulprim .
Sumetrolim .
TMP SMX .
TMP-SMX .
Trimedin .
Trimethoprim-Sulfamethoxazole .
Trimethoprimsulfa .
Trimezole .
Trimosulfa .
Biseptol 480 .
Biseptol480 .
Co Trimoxazole .
Sulfamethoxazole Trimethoprim Combination .
Trimethoprim Sulfamethoxazole .
Trimethoprim Sulfamethoxazole Combination .
Cotrimoxazole .
Trimethoprim-Sulfamethoxazole Combination .
Trimethoprim, Sulfamethoxazole Combination .
A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS. .
1.00
2446387
 
Pefloxacin .
2589 R.B. .
Abactal .
Peflacine .
Pefloxacin Mesylate .
Pefloxacin Mesylate Dihydrate .
Pefloxacine .
Silver Pefloxacin .
Dihydrate, Pefloxacin Mesylate .
Mesylate Dihydrate, Pefloxacin .
Mesylate, Pefloxacin .
Pefloxacin, Silver .
R.B., 2589 .
A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria. .
0.78
16819
 
Temefos .
Abate .
Difos .
Temephos .
Temephos .
An organothiophosphate insecticide. .
0.68
68329
 
Abatacept .
BMS 188667 .
BMS-188667 .
BMS-224818 .
BMS224818 .
Belatacept .
CTLA-4-Ig .
CTLA4-Fc .
CTLA4-Ig .
CTLA4-Ig Immunoconjugate .
Cytotoxic T Lymphocyte-Associated Antigen 4-Immunoglobulin .
LEA29Y .
Nulojix .
Orencia .
BMS 224818 .
BMS188667 .
CTLA4 Ig Immunoconjugate .
Cytotoxic T Lymphocyte Associated Antigen 4 Immunoglobulin .
Immunoconjugate, CTLA4-Ig .
A fusion protein immunoconjugate of the extracellular domain of CTLA4 and the Fc domain of human IgG1. It functions as a T-cell co-stimulation blocker that inhibits TNF-ALPHA and prevents the activation of T-LYMPHOCYTES. It is used in the treatment of RHEUMATOID ARTHRITIS. .
0.57
152532
 
Abattoirs .
Slaughter House .
Slaughter Houses .
Abattoir .
House, Slaughter .
Houses, Slaughter .
Slaughterhouse .
Slaughterhouses .
Places where animals are slaughtered and dressed for market. .
0.54
2855038
 
Conversion Disorder .
Conversion Reaction .
Astasia Abasia .
Conversion Disorders .
Conversion Hysteria .
Conversion Hysterias .
Conversion Reactions .
Hysterias, Conversion .
Reaction, Conversion .
Reactions, Conversion .
Astasia-Abasia .
Globus Hystericus .
Hysteria, Conversion .
A disorder whose predominant feature is a loss or alteration in physical functioning that suggests a physical disorder but that is actually a direct expression of a psychological conflict or need. .
0.47
532095
 
Prenalterol .
A-Ba-C-50,005 .
H-133-22 .
H-80-62 .
KWD-2033 .
Prenalterol Hydrochloride .
A Ba C 50,005 .
ABaC50,005 .
H13322 .
H8062 .
Hydrochloride, Prenalterol .
KWD2033 .
A partial adrenergic agonist with functional beta 1-receptor specificity and inotropic effect. It is effective in the treatment of acute CARDIAC FAILURE, postmyocardial infarction low-output syndrome, SHOCK, and reducing ORTHOSTATIC HYPOTENSION in the SHY-RAGER SYNDROME. .
0.46
1300